Arbutus’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award
September 13 2016 - 7:00AM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that Dr. Michael J. Sofia, Arbutus’ Chief Scientific
Officer, has been awarded the 2016 Lasker~DeBakey Clinical Medical
Research Award for the development of a revolutionary treatment of
hepatitis C virus (HCV). Dr. Sofia now leads a world class team of
scientists at Arbutus that is focused on developing innovative
therapies to improve cure rates in HBV.
“It is a tremendous honor to receive the
Lasker~DeBakey Award for Clinical Medical Research, in recognition
of the work that led to the discovery of sofosbuvir. Sofosbuvir is
the backbone of HCV curative regimens which have given new hope to
the 170 million HCV sufferers worldwide,” said Dr. Michael J.
Sofia, Arbutus’ Chief Scientific Officer. “Now that there is
a cure for HCV, I am excited to be working with my colleagues at
Arbutus to develop a cure for chronic HBV infection, an unmet
medical need that affects an even larger worldwide patient
population.”
For 71 years, the Lasker Awards, America’s most
prestigious biomedical research awards, have recognized the
contributions of scientists, clinicians, and public citizens who
have made major advances in the understanding, diagnosis,
treatment, cure, or prevention of human disease. Recipients of the
Lasker Medical Research Awards are selected by a distinguished
international jury chaired by Dr. Joseph L. Goldstein, recipient of
the 1985 Lasker Award for Basic Medical Research and the Nobel
Prize in Physiology or Medicine. Eighty-seven Lasker laureates have
received the Nobel Prize, including 41 in the last three
decades.
About Arbutus Arbutus Biopharma
Corporation is a biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for patients
suffering from chronic hepatitis B infection. Arbutus is
headquartered in Vancouver, BC, Canada with offices in Doylestown,
PA, USA. For more information, visit www.arbutusbio.com.
About the Albert and Mary Lasker
FoundationFounded in 1942, the Albert and Mary Lasker
Foundation envisions a healthier world through the advancement of
medical research. It seeks to improve health by accelerating
support for medical research through recognition of research
excellence, education, and advocacy. For much of the 20th century,
the Foundation was led by Mary Lasker, who was America's most
prominent citizen-activist for public investment in medical
research. She is widely credited with motivating the White House
and Congress to greatly expand federal funding for medical
research, particularly through the NIH. For more information on the
Lasker Award recipients, the full citations for each award
category, video interviews and photos of the awardees, and
additional information on the Foundation please refer to
www.laskerfoundation.org.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Senior Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024